-
公开(公告)号:US10259876B2
公开(公告)日:2019-04-16
申请号:US15402760
申请日:2017-01-10
Applicant: PFIZER INC.
Inventor: Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: A61K35/17 , C12N9/64 , A61K31/436 , C12N15/62 , C07K16/28 , C07K14/725 , C07K14/47 , A61K39/00 , A61K38/00
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号:US20170210811A1
公开(公告)日:2017-07-27
申请号:US15402760
申请日:2017-01-10
Applicant: PFIZER INC.
Inventor: Oi Kwan WONG , Joyce Ching CHOU , Mathilde Brunnhilde DUSSEAUX , Julianne Smith
IPC: C07K16/28 , C07K14/725
CPC classification number: C07K16/2863 , A61K38/00 , A61K2039/505 , C07K14/4748 , C07K14/7051 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03 , C07K2319/33
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号:US20220227874A1
公开(公告)日:2022-07-21
申请号:US17586321
申请日:2022-01-27
Applicant: Pfizer Inc.
Inventor: Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: C07K16/28 , C07K14/47 , C07K14/725
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号:US11267892B2
公开(公告)日:2022-03-08
申请号:US16255348
申请日:2019-01-23
Applicant: Pfizer Inc.
Inventor: Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: A61K35/17 , C12N9/64 , A61K31/436 , C07K16/28 , C07K14/47 , C07K14/725 , A61K38/00 , A61K39/00
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
-
-